Eisai’s Insomnia Treatment Lemborexant Smashes Primary Target in Long-Term PIII Study

Eisai and US-based Purdue Pharma’s investigational insomnia disorder treatment lemborexant (development code: E2006) has hit its primary and secondary targets in a long-term PIII clinical study against placebo, according to a six-month interim analysis published by the companies on October...read more